Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Randomized, Placebo-controlled, Double Blind Trial to Investigate Whether Vitamin K2 Can Influence Arterial Calcification in Patients With Type 2 Diabetes

Conditions:   Arterial Calcification;   Diabetes Mellitus Type 2
Interventions:   Dietary Supplement: Menaquinone-7;   Dietary Supplement: Placebo
Sponsor:   UMC Utrecht
Recruiting - verified July 2016

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Not yet recruiting - verified July 2016

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Irbesartan/atorvastatin fixed dose combination;   Drug: Irbesartan SR47436;   Drug: Atorvastatin
Sponsor:   Sanofi
Not yet recruiting - verified July 2016

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sub cutaneous liraglutide;   Drug: Oral Vildagliptin
Sponsors:   Yaounde Central Hospital;   University of Yaounde 1;   University of Buea
Recruiting - verified July 2016

Effect of a Continuous Glucose Monitoring on Maternal and Neonatal Outcomes in Gestational Diabetes Mellitus

Condition:   GDM
Interventions:   Device: FreeStyle sensors.;   Device: Glucometer
Sponsor:   Tel-Aviv Sourasky Medical Center
Not yet recruiting - verified July 2016

Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE;   Drug: metformin;   Drug: repaglinide;   Drug: acarbose;   Drug: sitagliptin
Sponsor:   Sanofi
Not yet recruiting - verified July 2016

The Canadian E-PAraDiGM (Exercise Physical Activity and Diabetes Glucose Monitoring) Protocol

Conditions:   Walking;   Seated Control
Interventions:   Behavioral: Walking;   Behavioral: Seated Control
Sponsors:   University of British Columbia;   University of Alberta;   University of Calgary;   McMaster University;   Universite de Sherbrooke;   Centre Hospitalier de l'Université Laval;   Children's Hospital Research Institute of Manitoba;   Medtronic
Recruiting - verified July 2016

Metabolic Effects of Stevia in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus
Intervention:   Dietary Supplement: Stevia rebaudiana liquid extract
Sponsor:   Yaounde Central Hospital
Active, not recruiting - verified July 2016

Diabetes Complication Control in Community Clinics (D4C) Trial

Conditions:   Diabetes;   Hypertension;   Dyslipidemia;   Cardiovascular Disease
Intervention:   Other: Protocol-based integrated care
Sponsors:   Tulane University Health Sciences Center;   Xiamen Diabetes Institute, Xiamen University, Xiamen, China
Not yet recruiting - verified July 2016

Wolfram Syndrome International Registry and Clinical Study

Conditions:   Wolfram Syndrome;   Diabetes Mellitus;   Optic Nerve Atrophy;   Deafness;   Diabetes Insipidus;   Ataxia
Intervention:  
Sponsors:   Washington University School of Medicine;   American Diabetes Association;   National Institutes of Health (NIH)
Recruiting - verified July 2016

Enhancing Self-Management Support in Diabetes Through Patient Engagement

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Enhanced Engagement Protocol for CTH (EE-CTH);   Behavioral: Connection to Health (CTH)
Sponsors:   University of California, San Francisco;   University of Colorado, Denver
Not yet recruiting - verified July 2016

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Condition:   Obesity, Visceral
Interventions:   Drug: [U-13C3] glycerol;   Drug: Empagliflozin;   Drug: Placebo (for Empagliflozin)
Sponsors:   University of Texas Southwestern Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2016

Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Gemigliptin;   Drug: Gemigliptin placebo;   Drug: Metformin;   Procedure: Diet/exercise questionnaire
Sponsor:   LG Life Sciences
Not yet recruiting - verified July 2016

Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)

Conditions:   Pre-diabetes;   Diabetes
Intervention:   Procedure: Not applicable. This is an observational study.
Sponsors:   Medicine;   Janssen Pharmaceuticals;   National Medical Research Council (NMRC), Singapore
Recruiting - verified July 2016

A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease

Condition:   Diabetic Chronic Kidney Disease
Intervention:   Biological: Neo-Kidney Augment (NKA)
Sponsors:   RegenMed (Cayman) Ltd.;   CTI Clinical Trial and Consulting Services
Not yet recruiting - verified July 2016

Effect of FISH Intake on MEtabolic Health in a Diabetic South Asian popuLation (FISH MEAL)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Tinned mackerel fish
Sponsor:   University of Aberdeen
Not yet recruiting - verified July 2016

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Metformin IR
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified July 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone
Sponsor:   Sanofi
Recruiting - verified July 2016

Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Oral administration of Ipragliflozin
Sponsors:   Asan Medical Center;   Severance Hospital;   Samsung Medical Center;   Kyung Hee University Hospital at Gangdong;   Astellas Pharma Korea, Inc.
Recruiting - verified July 2016

Shared Medical Visits for Spanish-speaking Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Intervention:   Behavioral: Shared Medical Visit
Sponsor:   University of Nebraska
Recruiting - verified July 2016

The Efficacy and Safety of Chinese Herbal Medicine YH1 as Add-On Medication in Poorly Controlled Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: YH1;   Drug: placebo
Sponsor:   Chang Gung Memorial Hospital
Recruiting - verified March 2016

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified July 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified July 2016

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified July 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified July 2016

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Recruiting - verified July 2016

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Validation of an Integrated Attention Model for Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Behavioral: CAIPaDi
Sponsor:   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Recruiting - verified July 2016

Effect of Non Surgical Treatment of Periodontitis on Diabetes Control

Conditions:   Periodontitis;   Diabetes
Intervention:   Procedure: non-surgical periodontal treatment
Sponsor:   Yaounde Central Hospital
Completed - verified July 2016

An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Janssen-Cilag International NV
Active, not recruiting - verified July 2016

A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY900014;   Drug: Insulin Lispro
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified July 2016

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified May 2016

Intraluminal Imaging of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Procedure: EUS and OCT imaging
Sponsor:   Victoria Gomez
Enrolling by invitation - verified July 2016

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin;   Drug: Repaglinide;   Drug: Pioglitazone;   Drug: Gliclazide;   Drug: Glimepiride
Sponsors:   University of Leicester;   University Hospital Birmingham
Recruiting - verified July 2016

Translating Healthy Lifestyle Interventions for Cancer Survivors

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   Breast Cancer;   Endometrial Cancer
Intervention:   Behavioral: Standard Behavioral Weight Change Intervention
Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified July 2016

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus,;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Placebo for Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lyophilized albiglutide DCC pen injector;   Drug: Lyophilized albiglutide DCC pen injector matching placebo;   Drug: Albiglutide liquid auto-injector;   Drug: Albiglutide liquid auto-injector matching placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified July 2016

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: ITCA 650 60 mcg/day
Sponsor:   Intarcia Therapeutics
Recruiting - verified July 2016

INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: Intervention 1;   Other: Intervention 2
Sponsors:   Jordi Gol i Gurina Foundation;   Sanofi
Recruiting - verified July 2016

A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin Lispro
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified July 2016

Canagliflozin-Mealtime Insulin Rescue

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: canagliflozin;   Drug: placebo
Sponsors:   Atlanta Research and Education Foundation;   Janssen Scientific Affairs, LLC
Recruiting - verified July 2016

Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: INSULIN GLARGINE
Sponsor:   Sanofi
Recruiting - verified July 2016

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified July 2016

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Placebo;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

Conditions:   Diabetes Mellitus, Type 2;   Coronary Artery Disease;   Cardiovascular Diseases
Interventions:   Drug: RVX000222;   Drug: Placebo (for RVX000222);   Drug: atorvastatin;   Drug: rosuvastatin
Sponsors:   Resverlogix Corp;   PPD;   ICON plc;   Medidata Solutions
Recruiting - verified July 2016

Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

Conditions:   Dyslipidemia;   Type II Diabetes
Interventions:   Drug: YH14755;   Drug: Metformin;   Drug: Rosuvastatin
Sponsor:   Yuhan Corporation
Recruiting - verified July 2016

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PF-06291874;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2016

A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MEDI0382;   Drug: Placebo
Sponsor:   MedImmune LLC
Recruiting - verified July 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2016

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin;   Drug: Sulfonylurea
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

Condition:   Type 2 Diabetes Mellitus
Intervention:   Biological: Bydureon
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

Conditions:   Chronic Kidney Disease;   Type 2 Diabetes
Intervention:   Biological: Neo-Kidney Augment
Sponsors:   RegenMed (Cayman) Ltd.;   CTI Clinical Trial and Consulting Services
Enrolling by invitation - verified July 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Conditions:   Essential Hypertension;   Type 2 Diabetes Mellitus
Intervention:   Drug: Azilsartan Medoxomil
Sponsor:   Takeda
Recruiting - verified July 2016

Online Support for Diabetes Self-Management

Condition:   Diabetes Mellitus Type 2
Intervention:   Behavioral: Online Support
Sponsors:   University of British Columbia;   University of Minnesota - Clinical and Translational Science Institute
Terminated - verified July 2016

Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes - Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients - The Phenotype Study

Condition:   Type 2 Diabetes
Interventions:   Other: Low carbohydrate meals;   Other: Standard carbohydrate meals
Sponsor:   Bispebjerg Hospital
Recruiting - verified July 2016

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus

Condition:   Diabetes Mellitus Gestational Previous Pregnancy
Intervention:   Behavioral: Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus
Sponsor:   Athabasca University
Recruiting - verified July 2016

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: ASP1941;   Drug: Placebo
Sponsor:   Astellas Pharma Korea, Inc.
Active, not recruiting - verified July 2016

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified July 2016

FreeStyle Libre Pro Use in Primary & Secondary Care

Condition:   Diabetes Mellitus
Interventions:   Device: FreeStyle Libre Pro 4 sensor wears, 2 with reviews;   Device: FreeStyle Libre Pro 6 sensor wears, 4 with reviews;   Device: FreeStyle Libre Pro 3 sensor wears
Sponsor:   Abbott Diabetes Care
Active, not recruiting - verified July 2016

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified July 2016

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Bexagliflozin tablets;   Drug: Bexagliflozin tablets, placebo
Sponsor:   Theracos
Completed - verified July 2016

Effectiveness of Automated Mobile Phone Based Text Messaging on the Improvement of Glycaemic Outcomes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Mobile phone text messaging;   Other: Conventional care
Sponsor:   India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
Active, not recruiting - verified July 2016

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

Condition:   Diabetes Prevention in Women After GDM Who Are at High-risk
Interventions:   Drug: DAPA/MET XR;   Drug: DAPA;   Drug: MET XR
Sponsors:   Woman's;   AstraZeneca
Recruiting - verified July 2016

Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Interventions:   Procedure: Bariatric surgery involving Roux-en-Y gastric bypass;   Procedure: Bariatric surgery involving Laparoscopic adjustable gastric banding;   Procedure: Bariatric surgery involving Laparoscopic sleeve gastrectomy
Sponsors:   The Cleveland Clinic;   Medtronic - MITG;   Ethicon, Inc.
Enrolling by invitation - verified July 2016

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Effect of Cycloset on Glycemic Control When Added to GLP-1 Analogue Therapy

Condition:   Type 2 Diabetes
Intervention:   Drug: Cycloset
Sponsors:   The University of Texas Health Science Center at San Antonio;   VeroScience
Recruiting - verified July 2016

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Ono Pharmaceutical Co. Ltd
Active, not recruiting - verified July 2016

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2016

Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Completed - verified July 2016

Continuous Glucose Monitoring in Controls With and Without Cystic Fibrosis

Condition:   Cystic Fibrosis
Intervention:  
Sponsor:   University of Colorado, Denver
Recruiting - verified July 2016

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Evaluating the Impact of Year Long, Augmented Diabetes Self Management Support

Condition:   Diabetes Mellitus Type 2
Intervention:   Other: diabetes self management support
Sponsors:   American Association of Diabetes Educators;   Bristol-Myers Squibb
Active, not recruiting - verified July 2016

Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Mitiglinide;   Drug: Acarbose
Sponsor:   Zhongda Hospital
Completed - verified July 2016

Translating Telephonic Diabetes Self-management Support to Primary Care Practice

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Telephonic Diabetes Self-Management Support;   Other: Educational Print Materials
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   New York City Department of Health and Mental Hygiene
Recruiting - verified July 2016

Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified July 2016

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified July 2016

Efficacy and Safety of Voglibose Compared With Acarbose in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin;   Drug: Voglibose;   Drug: Acarbose
Sponsor:   Takeda
Completed - verified July 2016

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
Interventions:   Drug: APD356-Lorcaserin hydrochloride;   Drug: Placebo
Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
Active, not recruiting - verified July 2016

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Drug: Liraglutide;   Drug: Metformin
Sponsor:   University of Miami
Recruiting - verified July 2016

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Cardiovascular Disease
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Placebo;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

Condition:   Patients With Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution
Intervention:   Drug: Alogliptin
Sponsor:   Takeda
Completed - verified July 2016

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

The Effect of Linagliptin on Mitochondrial and Endothelial Function

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: Linagliptin;   Drug: Placebo;   Other: Microcirculation testing;   Other: Macrocirculation testing;   Other: MRI Scans
Sponsor:   Beth Israel Deaconess Medical Center
Completed - verified July 2016

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified July 2016

Evaluation of a Nutritional Supplement for People With Type 2 Diabetes.

Condition:   Diabetes
Interventions:   Other: Experimental Study Product;   Other: Control Study Product
Sponsor:   Abbott Nutrition
Withdrawn - verified July 2016

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

Condition:   Disorder of Glucose Regulation
Interventions:   Drug: Sitagliptin-Metformin;   Drug: Metformin;   Drug: Placebo pill
Sponsors:   Woman's;   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy

Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Diabetic Polyneuropathy;   Hereditary Axonal Neuropathy;   Hereditary Demyelinated Neuropathy;   Polyneuropathy, Inflammatory Demyelinating, Chronic
Intervention:  
Sponsors:   Aarhus University Hospital;   University of Southern Denmark
Recruiting - verified July 2016

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified July 2016

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Comparative Effectiveness of Glycemia-lowering Medications
Interventions:   Drug: Sulfonylurea (glimepiride);   Drug: DPP-4 inhibitor (sitagliptin);   Drug: GLP-1 receptor agonist (liraglutide);   Drug: Insulin (glargine)
Sponsors:   GRADE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Heart, Lung, and Blood Institute (NHLBI);   Becton, Dickinson and Company;   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.;   Novo Nordisk A/S;   Hoffmann-La Roche;   Sanofi
Recruiting - verified July 2016

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Eye Blood Flow and the Kidney

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Captopril;   Drug: placebo
Sponsor:   Brigham and Women's Hospital
Recruiting - verified July 2016

Biomarkers of Diabetic Retinopathy Progression

Conditions:   Type 2 Diabetes Mellitus;   Mild Nonproliferative Diabetic Retinopathy
Intervention:  
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Active, not recruiting - verified July 2016

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified July 2016

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified July 2016

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

Conditions:   Insulin Sensitivity;   Multiple Mitochondrial Dysfunctions Syndrome
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2016

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Exenatide;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Amylin Pharmaceuticals, LLC.;   Eli Lilly and Company
Completed - verified July 2016

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation - verified July 2016

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (HOE901);   Drug: INSULIN GLULISINE (HMR1964)
Sponsor:   Sanofi
Completed - verified July 2016

Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients

Condition:   Osseointegration Failure of Dental Implant From Complication of Systemic Disease
Intervention:  
Sponsors:   University of Alabama at Birmingham;   Dentsply Implants
Active, not recruiting - verified June 2016

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

Condition:   Diabetes
Interventions:   Drug: metformin\pioglitazone\exenatide;   Drug: metformin, glyburide and glargine
Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association;   Amylin Pharmaceuticals, LLC.
Recruiting - verified July 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2016

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: exenatide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified July 2016

A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes

Conditions:   Diabetes;   Type 1 Diabetes Mellitus;   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Baylor College of Medicine
Completed - verified July 2016

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified July 2016

Empowering Patients to Better Manage Diabetes Through Self-Care

Condition:   Type I or Type II Diabetes (Excludes Gestational Diabetes)
Interventions:   Behavioral: Pharmacist Counseling;   Behavioral: Educational materials
Sponsors:   Oregon State University;   Sanofi
Completed - verified July 2016